Mirae Asset Global ETFs Holdings
RIGL icon

Mirae Asset Global ETFs Holdings’s Rigel Pharmaceuticals RIGL Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Sell
10,572
-528
-5% -$16.3K ﹤0.01% 2098
2026
Q1 		$297K Buy
11,100
+413
+4% +$13.9K ﹤0.01% 2159
2025
Q4 		$458K Buy
10,687
+1,886
+21% +$71.1K ﹤0.01% 1936
2025
Q3 		$250K Sell
8,801
-1,814
-17% -$54.3K ﹤0.01% 2210
2025
Q2 		$200K Sell
10,615
-751
-7% -$14.2K ﹤0.01% 2288
2025
Q1 		$204K Buy
11,366
+1,464
+15% +$29.7K ﹤0.01% 2309
2024
Q4 		$167K Buy
9,902
+278
+3% +$5.33K ﹤0.01% 2472
2024
Q3 		$156K Buy
9,624
+1,001
+12% +$11.8K ﹤0.01% 2492
2024
Q2 		$70.9K Buy
+8,623
New +$90.3K ﹤0.01% 2694

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's RIGL Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Rigel Pharmaceuticals (RIGL) stake by 4.8% in Q2 2026, selling an estimated $16.3K and leaving 10,572 shares worth $413K. The position accounts for ﹤0.01% of the portfolio, ranked #2098.

Mirae Asset Global ETFs Holdings first reported a position in RIGL in Q2 2024 and has held it in 9 quarters since. The position peaked at $458K in Q4 2025. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 10,572 shares of Rigel Pharmaceuticals worth $413K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings sold 528 Rigel Pharmaceuticals shares in Q2 2026, an estimated $16.3K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2098 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Rigel Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global ETFs Holdings's Rigel Pharmaceuticals position peaked at $458K in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.